SAN DIEGO, Antiplatelet drug ticagrelor (Brilinta®) works faster and is more effective in blocking platelet activity in low-risk patients with acute coronary syndrome (ACS) than clopidogrel, ...
March 6, 2009 (Munich, Germany) — More evidence that patients with a low platelet responsiveness to clopidogrel have an increased risk of stent thrombosis has come from a new study, with the ...
December 4, 2009 (Munich, Germany) - Patients undergoing PCI who had an enhanced response to clopidogrel as assessed by a platelet-function test had three times the risk of major bleeding compared ...
AstraZeneca today announced the results of the phase II studies, ONSET/OFFSET and RESPOND for ticagrelor (BRILINTA) at the annual American Heart Association (AHA) Scientific Sessions in Orlando, FL, ...
A new study, published in the November 17, 2009, issue of the Journal of the American College of Cardiology, adds to a growing body of research seeking to evaluate and understand possible sex ...
Managing drug dosage is critical to the overall success of pharmaceutical intervention, not only in the clinic but also in clinical trials. Inadequate dose management of certain drugs can have fatal ...
PARIS/LONDON (Reuters) - French drugmaker Sanofi-Aventis is preparing to sell its own generic version of the blockbuster heart medicine Plavix in France, a company spokesman said on Monday. Plavix, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results